Eli Lilly (NYSE: LLY) stock has had plenty of good trading sessions over the past year or so, but Monday's sure wasn't among ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

In the ever-evolving landscape of healthcare, groundbreaking innovations are not merely celebrated for their scientific ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible worldwide, as ...

Participants treated with CagriSema achieved weight loss of 15.7% after the 68-week duration of ... They also punished fellow obesity drug developers like Eli Lilly in a sympathy sell-off.

Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.

Novo Nordisk announced launching a direct-to-patient online pharmacy NovoCare, offering a more than half-price cut for its ...

Roche has signed the biggest-ever obesity drug deal with a $5.3bn licensing agreement for a next-generation treatment from ...